Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosi
Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits
What it measured
Main measures
Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis
Other measures (1)
Assess correlation between antibody levels to various infectious agents with clinical disease variables
Who could take part
MS (type not specified) · 18 to 50
Show the full criteria
Inclusion criteria
* Definite multiple sclerosis
Exclusion criteria
* Intravenous immune globulin (IVIg) treatment
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori in a group of patients presenting with specific autoimmune diseases (rheumatoid arthritis [RA], undifferentiated connective tissue disorder [UCTD], Sjogren, antiphospholipid syndrome - APS, vasculitides, systemic lupus erythematosus [SLE], polymyositis, Hashimoto, multiple sclerosis, primary biliary cirrhosis [PBC], etc.), using the BioPlex 2200 and complementary EIA kits as compared to matched controls (by age, sex and ethnicity).
Loading reviews and guidelines…
History
Started
Sept 2005
Finished
Apr 2006